Case Report

Surgical Bailout Therapy after Implantation of a Medtronic CoreValve Bioprosthesis

Rita Calé,1 José Neves,2 Rui Teles,1 João Brito,1 Miguel Abecasis,2 Manuel Almeida,1 Tiago Nolasco,2 and Miguel Mendes1

1 Cardiology Department, Santa Cruz Hospital, Lisbon, Portugal
2 Cardiac Surgery Department, Santa Cruz Hospital, Lisbon, Portugal

Correspondence should be addressed to Rita Calé, ritacale@hotmail.com

Received 14 April 2012; Accepted 12 July 2012

Copyright © 2012 Rita Calé et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Moderate-to-severe paraprosthetic leak causing hemodynamic deterioration and left ventricular remodeling can occur after transcatheter aortic valve implantation (TAVI) [1]. There are several percutaneous techniques already described to manage early implant failure [2]. Nevertheless, the surgical bailout therapy has not been described after TAVI using the Medtronic Core Valve bioprosthesis (Medtronic, Minneapolis, MN).

2. Case Report

A 75-year-old female with worsening exertional dyspnea and angina for the previous 10 months was referred for cardiology evaluation. She had several cardiovascular risk factors (hypertension, diabetes, hyperlipidaemia and a morbid obesity with a BMI of 40), chronic lung disease, and renal chronic insufficiency with a calculated creatinine clearance of 38 mL/min. On the transthoracic echocardiogram, a severe stenosis aortic was diagnosed with an aortic orifice area of 0.7 cm² and a systolic left ventricle dysfunction with an ejection fraction of 38%. Coronary angiography showed coronary arteries without lesions and good femoral accesses. The intraoperative transesophageal echocardiogram confirmed a heavy calcified aortic valve with an annulus of 21 mm. The transfemoral implantation of the 26 mm CoreValve prosthesis was complicated with acute left ventricle dilatation due to a severe paravalvular leak. Patient was unresponsive to elective balloon post-dilatation, and therefore she was successfully treated with open-heart surgery to remove the malfunctioning CoreValve bioprosthesis and perform standard aortic valve replacement.
Figure 1: Transesophageal echocardiography images (intercomissural long axis view (a), short axis view (b)) after transcatheter valve implantation demonstrated a moderate paravalvular aortic regurgitation.

Figure 2: Fluoroscopy and angiographic images showing a deep implantation of the 26 mm CoreValve prosthesis (a) and its repositioning with a snair (b).

Figure 3: Angiotomography view showing a 26 mm CoreValve prosthesis in long-axis (a) and short-axis view (b) in an adequate position although underexpansion (white arrows).

22 mm was done without clear clinical or echocardiography improvement. The patient had a decompensated heart failure refractory to medical treatment and, despite the high-operative risk, we decided to perform an aortic valve replacement via standard median sternotomy. The 26 mm CoreValve prosthesis was removed and replacement of the aortic valve using 21 mm Mitroflow was done (Figure 4).

The postoperative period was complicated by worsened renal failure requiring dialysis and paroxysmal atrial fibrillation but the patient was discharged without dyspnea two months later. Transthoracic echocardiography at discharged showed a normal prosthetic valve function and a slight improvement on left ventricle dimensions and function, although not completely normal.
3. Discussion

After TAVI, a significant paravalvular leak can occur for several reasons: undersized prosthesis, malposition of the device (very deep or high implantation), prosthesis underexpansion, the presence of heavily calcified stenotic aortic valve or a bicuspid valve [4]. With the currently available devices, it is very difficult to fully reposition the bioprosthesis after initial deployment. Several bailout transcatheter techniques have been described to manage suboptimal prosthesis deployment: a postdilatation, snair repositioning, or valve-in-valve technique with implantation of a second device inside the first one [2, 4–7]. In the present case, there was more than one possible mechanism for the development of this severe paravalvular leak: the first explanation was deep valve implantation, but this was resolved intraprocedure by repositioning the prosthesis with a snair and documented by angio-CT. A second possible mechanism was underexpansion, as angiotomography scan evidenced, but a postdilatation did not improve clinical or echocardiography status. This was probably related to insufficient oversizing of the transcatheter valve with respect to the patient’s aortic annulus and the severity and asymmetric distribution of valve calcification. The implantation of a second valve might be associated with an increase of the radial force [6], although “valve-in-valve” procedure, eventually with a balloon expandable, is mainly indicated to acutely manage device malposition.

Despite the absence of such case reports, our heart team decided to undergo an open-heart surgery, to remove the malfunctioning CoreValve bioprosthesis and perform standard aortic valve replacement. Cardiac surgery was successful, although complicated by acute renal failure requiring dialysis. We can also discuss percutaneous valve-in-valve procedure as an alternative strategy.

Presently there is scarce data on paravalvular leak predictors. As other authors have already suggested [4, 6], there is a need to better predict and assess ominous prognosis caused by paravalvular leaks after TAVI and to determine the role of different strategies for the treatment of each mechanism.

4. Conclusion

The surgical bailout therapy by implanting a second aortic bioprosthesis through conventional surgery after removing the first malfunctioning CoreValve bioprosthesis in a high-risk patient is possible, with good results and without major complications. In the future, the development of percutaneous bioprosthesis that reduce paravalvular leaks and allow valve retrieval and reposition after suboptimal deployment could avoid the need of surgical bailout therapy.

Conflict of Interests

The authors have no conflict of interests to declare.
References

[1] M. A. Sherif, M. Abdel-Wahab, B. Stöcker et al., “Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis,” *Journal of the American College of Cardiology*, vol. 56, no. 20, pp. 1623–1629, 2010.

[2] G. P. Ussia, M. Barbanti, S. Immè et al., “Management of implant failure during transcatheter aortic valve implantation,” *Catheterization and Cardiovascular Interventions*, vol. 76, no. 3, pp. 440–449, 2010.

[3] W. A. Zoghbi, J. B. Chambers, J. G. Dumesnil et al., “Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound,” *Journal of the American Society of Echocardiography*, vol. 22, no. 9, pp. 975–1014, 2009.

[4] D. Détaint, L. Lepage, D. Himbert et al., “Determinants of significant paravalvular regurgitation after transcatheter aortic valve implantation. Impact of Device and Annulus Discongruence,” *Journal of the American College of Cardiology*, vol. 2, no. 9, pp. 821–827, 2009.

[5] G. P. Ussia, M. Barbanti, A. Ramondo et al., “The valve-in-valve technique for treatment of aortic Bioprosthesis malposition: an analysis of incidence and 1-year clinical outcomes from the Italian CoreValve Registry,” *Journal of the American College of Cardiology*, vol. 57, no. 9, pp. 1062–1068, 2011.

[6] J. Rodés-Cabau, E. Dumont, and D. Doyle, “‘Valve-in-valve’ for the treatment of paravalvular leaks following transcatheter aortic valve implantation,” *Catheterization and Cardiovascular Interventions*, vol. 74, no. 7, pp. 1116–1119, 2009.

[7] A. C. T. Ng, F. van der Kley, V. Delgado et al., “Percutaneous valve-in-valve procedure for severe paravalvular regurgitation in aortic bioprosthesis,” *Journal of the American College of Cardiology*, vol. 2, no. 4, pp. 522–523, 2009.